Novavax Opens Its First U.S. Vac...( Company State and County Representat...)

Company, State and County Representatives Unveil State-of-the-Art Facility

in Rockville, MD

ROCKVILLE, Md., May 1 /PRNewswire-FirstCall/ -- Officials from Novavax, Inc. (Nasdaq: NVAX), the State of Maryland and Montgomery County today celebrated the opening of Novavax's new state-of-the-art vaccine production facility at the company's headquarters in Rockville, Maryland. The 5,000 square-foot, $5 million pilot and commercial-scale manufacturing plant will be used to produce vaccines addressing a broad range of infectious diseases. The facility will initially supply influenza vaccine for the company's current clinical programs with planned annual capacity of 10 million doses.

"The completion of this facility represents a major milestone for Novavax and a significant accomplishment for our development team," said Novavax president and chief executive officer Rahul Singhvi, Sc.D. "This facility is seen as a model vaccine plant for production of all of our virus-like-particle-based vaccines and will serve as a prototype for other similar local country facilities through collaborators such as GE Healthcare. It incorporates new processes that are designed to increase production yields with significantly less infrastructure and capital cost compared to current approved vaccine facilities. Our production technology, which can be used to produce many types of vaccines in a single facility, combined with our use of disposable materials, offer the potential advantage of simple portability of production equipment to sites around the world, where vaccines may be urgently needed."

Unlike traditional egg-based vaccine production, which is expensive and can require large centralized manufacturing plants w
'/>"/>